Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Luis Murguia Favela"'
Publikováno v:
American Journal of Perinatology Reports, Vol 08, Iss 02, Pp e134-e137 (2018)
Healthy looking newborns may have severe combined immunodeficiency (SCID), and neonatologists frequently are the first physicians to encounter these patients. Physicians usually have a high index of suspicion for this condition in presence of certain
Externí odkaz:
https://doaj.org/article/7f7d6adf473e41d191fe20c4c97d00e0
Autor:
Patrick Sipila, Satbir Thakur, Mehr Malhotra, Chunfen Zhang, Lian Willetts, Luis Murguia-Favela, Aru Narendran
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/a79dc70efa9d486b948541bd1fd86241
Autor:
Satbir Thakur, Mohit Jain, Chunfen Zhang, Candice Major, Kevin J. Bielamowicz, Norman J. Lacayo, Olena Vaske, Victor Lewis, Luis Murguia-Favela, Aru Narendran
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 12, Pp 5558-5562 (2021)
There is experimental and clinical data to indicate the contribution of immune-escape mechanisms in relapsed/refractory pediatric leukemia. Studies have shown the accumulation of mutations that translate to peptides containing tumor-specific epitopes
Externí odkaz:
https://doaj.org/article/9b3da1f32ffe496189cb9a74e4580535
Publikováno v:
Cancers, Vol 14, Iss 23, p 5942 (2022)
Background: Cancer is the leading cause of disease-related mortality in children and malignancies are more frequently observed in individuals with primary immunodeficiencies (PIDs). This study aimed to identify and highlight the molecular mechanisms,
Externí odkaz:
https://doaj.org/article/194bdaa8712145ceba6f18a9366fdbef
Autor:
Luis Murguia-Favela, Sneha Suresh, Nicola A.M. Wright, Saima Alvi, Sarah Tehseen, Vivian Hernandez-Trujillo, Christine M. Seroogy, Elie Haddad, Daime Nieves, Michael S. Hershfield, Jolan E. Walter, Leah Pettiford, Naynesh R. Kamani, Michael D. Keller, Anne Pham-Huy, Eyal Grunebaum
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice.
Autor:
Grace E. McAuley, Gloria Yiu, Patrick C Chang, Gregory A. Newby, Beatriz Campo-Fernandez, Sorel T. Fitz-Gibbon, Xiaomeng Wu, Sung-Hae L. Kang, Amber Garibay, Jeffrey Butler, Valentina Christian, Ryan L. Wong, Kelcee A. Everette, Anthony Azzun, Hila Gelfer, Christopher S. Seet, Aru Narendran, Luis Murguia-Favela, Zulema Romero, Nicola Wright, David R. Liu, Gay M. Crooks, Donald B. Kohn
Publikováno v:
Cell. 186:1398-1416.e23
Autor:
Brenda Reid, Alison Haynes, Parwinder Gill, Julia Upton, Vy Hong-Diep Kim, Christine McCusker, Thomas B. Issekutz, Luis Murguia-Favela, Tamar S. Rubin, Kyla J. Hildebrand, Rae Brager, Chaim M. Roifman
Publikováno v:
LymphoSign Journal. 7:109-115
Adenosine deaminase (ADA) deficiency is a form of severe combined immunodeficiency. Aberrant mutations in the ADA gene result in loss of ADA activity and the toxic accumulation of metabolites that damage both immune and non-immune organs. While patie
Publikováno v:
Clin Exp Immunol
Summary The absence of adenosine deaminase (ADA) causes severe combined immune deficiency (SCID), which has been treated with PEGylated bovine-extracted ADA (ADAGEN). ADAGEN was recently replaced by a PEGylated recombinant bovine ADA, expressed in Es
Autor:
Danielle E. Arnold, Deepak Chellapandian, Suhag Parikh, Kanwaldeep Mallhi, Rebecca A. Marsh, Jennifer R. Heimall, Debra Grossman, Maria Chitty-Lopez, Luis Murguia-Favela, Andrew R. Gennery, Farid Boulad, Erin Arbuckle, Morton J. Cowan, Christopher C. Dvorak, Linda M. Griffith, Elie Haddad, Donald B. Kohn, Luigi D. Notarangelo, Sung-Yun Pai, Jennifer M. Puck, Michael A. Pulsipher, Troy Torgerson, Elizabeth M. Kang, Harry L. Malech, Jennifer W. Leiding
Publikováno v:
Journal of clinical immunology, vol 42, iss 5
Granulocyte transfusions are sometimes used as adjunctive therapy for the treatment of infection in patients with chronic granulomatous disease (CGD). However, granulocyte transfusions can be associated with a high rate of alloimmunization, and their
Autor:
Luis Murguia-Favela, Michele L. Ramien, Cora Constantinescu, Mark G. Kirchhof, Sylvia A. Martinez-Cabriales
Publikováno v:
American Journal of Clinical Dermatology
Dupilumab is the only biologic therapy currently approved in Europe and the United States for severe atopic dermatitis in patients 6 years of age or older. Off-label use is rationalized in younger children with severe atopic dermatitis. Decisions abo